• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16381 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Ontario Health Interferon-gamma release assay testing for latent tuberculosis infection: a health technology assessment
2024     Ontario Health Single-exposure, dual-energy subtraction flat panel x-ray detectors: a health technology assessment
2024     Ontario Health Peripheral nerve stimulation for chronic neuropathic pain: a health technology assessment
2024     Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non–small cell lung cancer: a health technology assessment
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse: a health technology assessment
2024     Ontario Health Fractional exhaled nitric oxide testing for the diagnosis and management of asthma: a health technology assessment
2024     Ontario Health Sucrose octosulfate (SOS)-impregnated dressings for adults with difficult-to-heal noninfected diabetic foot ulcers and difficult-to-heal noninfected venous leg ulcers
2024     Ontario Health Level 2 polysomnography for the diagnosis of sleep disorders: a health technology assessment
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     Ontario Health Minimally invasive bleb surgery for glaucoma: a health technology assessment
2024     Scottish Health Technologies Group (SHTG) Living Donor Transplantation - SHTG Assessment
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pharmacotherapy for transplant ineligible multiple myeloma
2024     NIHR Health Technology Assessment programme Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     NIHR Health Technology Assessment programme Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health Technology Assessment programme Cerclage suture type to prevent pregnancy loss in women requiring a vaginal cervical cerclage: the C-STICH RCT
2024     NIHR Health Technology Assessment programme Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     NIHR Health Technology Assessment programme Linkage of routinely collected NHS data to evaluate liaison mental health services: challenges and lessons learned
2024     NIHR Health Technology Assessment programme Infliximab versus alpha interferon in the treatment of Behçet’s disease: the BIO BEHÇET’S RCT
2024     NIHR Health Technology Assessment programme Development and evaluation of machine-learning methods in whole-body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer: the MALIBO diagnostic test accuracy study
2024     NIHR Health Technology Assessment programme Bezafibrate as treatment in males for Barth syndrome: CARDIOMAN, a double-blind, placebo-controlled crossover RCT
2024     NIHR Health Technology Assessment programme Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT
2024     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study
2024     NIHR Health Technology Assessment programme Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024     NIHR Health Technology Assessment programme Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2023     Institute for Clinical and Economic Review (ICER) Atidarsagene autotemcel for metachromatic leukodystrophy
2023     Institute for Clinical and Economic Review (ICER) Gene therapies for sickle cell disease
2023     Institute for Clinical and Economic Review (ICER) Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023     Institute for Clinical and Economic Review (ICER) Lecanemab for early Alzheimer’s disease
2023     Institute for Clinical and Economic Review (ICER) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023     Norwegian Institute of Public Health (NIPH) Stockholm3 test to estimate the risk of prostate cancer: a single technology assessment
2023     Norwegian Institute of Public Health (NIPH) Transcutaneous non-invasive vagus nerve stimulation (gammaCore) for the treatment of cluster headache: A single technology assessment
2023     Health Information and Quality Authority (HIQA) Review of national public health strategies in selected countries
2023     WorkSafeBC Cryoneurolysis for shoulder pain
2023     National Institute for Health and Care Excellence (NICE) MRI-based technologies for assessing non-alcoholic fatty liver disease. NICE diagnostics guidance 50
2023     National Institute for Health and Care Excellence (NICE) MRI fusion biopsy systems for diagnosing prostate cancer. NICE diagnostics guidance 53
2023     National Institute for Health and Care Excellence (NICE) Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers. NICE diagnostics guidance 52
2023     National Institute for Health and Care Excellence (NICE) Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2023     National Institute for Health and Care Excellence (NICE) FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. NICE diagnostics guidance 48
2023     National Institute for Health and Care Excellence (NICE) AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023     National Institute for Health and Care Excellence (NICE) Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023     National Institute for Health and Care Excellence (NICE) Devices for remote monitoring of Parkinson's disease. NICE diagnostics guidance 51
2023     National Institute for Health and Care Excellence (NICE) AposHealth for knee osteoarthritis. NICE medical technologies guidance 76
2023     Penn Medicine Center for Evidence-based Practice (CEP) Mortality review 2023 update
2023     National Institute for Health and Care Excellence (NICE) Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain. NICE interventional procedures guidance 747
2023     National Institute for Health and Care Excellence (NICE) Transcutaneous electrical stimulation of the trigeminal nerve for ADHD. NICE interventional procedures guidance 748
2023     National Institute for Health and Care Excellence (NICE) Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. NICE interventional procedures guidance 749
2023     National Institute for Health and Care Excellence (NICE) Trabeculectomy with a biodegradable collagen matrix implant for glaucoma. NICE interventional procedures guidance 750
2023     National Institute for Health and Care Excellence (NICE) Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. NICE interventional procedures guidance 752
2023     National Institute for Health and Care Excellence (NICE) Transvenous obliteration for gastric varices. NICE interventional procedures guidance 751
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transluminal renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 754
2023     National Institute for Health and Care Excellence (NICE) Endoluminal gastroplication for gastro-oesophageal reflux disease. NICE interventional procedures guidance 753
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation for palliation of painful spinal metastases. NICE interventional procedures guidance 758
2023     National Institute for Health and Care Excellence (NICE) Maximal cytoreductive surgery for advanced ovarian cancer. NICE interventional procedures guidance 757
2023     National Institute for Health and Care Excellence (NICE) Focal therapy using high-intensity focused ultrasound for localised prostate cancer. NICE interventional procedures guidance 756
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thoracic duct embolisation for persistent chyle leak. NICE interventional procedures guidance 755
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. NICE interventional procedures guidance 759
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided biliary drainage for biliary obstruction. NICE interventional procedures guidance 761
2023     National Institute for Health and Care Excellence (NICE) Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea. NICE interventional procedures guidance 760
2023     National Institute for Health and Care Excellence (NICE) Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. NICE interventional procedures guidance 762
2023     National Institute for Health and Care Excellence (NICE) Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer. NICE interventional procedures guidance 763
2023     National Institute for Health and Care Excellence (NICE) Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. NICE interventional procedures guidance 765
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. NICE interventional procedures guidance 764
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2023     National Institute for Health and Care Excellence (NICE) Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 766
2023     National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating prostate cancer. NICE interventional procedures guidance 768
2023     National Institute for Health and Care Excellence (NICE) Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease. NICE interventional procedures guidance 769
2023     National Institute for Health and Care Excellence (NICE) Cryotherapy for chronic rhinitis. NICE interventional procedures guidance 771
2023     National Institute for Health and Care Excellence (NICE) Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2023     National Institute for Health and Care Excellence (NICE) Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. NICE interventional procedures guidance 772
2023     National Institute for Health and Care Excellence (NICE) Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. NICE interventional procedures guidance 773
2023     National Institute for Health and Care Excellence (NICE) Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
2023     National Institute for Health and Care Excellence (NICE) Extracorporeal carbon dioxide removal for acute respiratory failure. NICE interventional procedures guidance 776
2023     National Institute for Health and Care Excellence (NICE) Biodegradable subacromial spacer insertion for rotator cuff tears. NICE interventional procedures guidance 775
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. NICE interventional procedures guidance 777
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. NICE interventional procedures guidance 778
2023     National Institute for Health and Care Excellence (NICE) Middle meningeal artery embolisation for chronic subdural haematomas. NICE interventional procedures guidance 779
2023     The Danish Health Technology Council (DHTC) [Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2023     The Danish Health Technology Council (DHTC) [Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2023     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023     National Institute for Health and Care Excellence (NICE) Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023     National Institute for Health and Care Excellence (NICE) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936
2023     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 935
2023     National Institute for Health and Care Excellence (NICE) Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms. NICE technology appraisal guidance 934
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2023     National Institute for Health and Care Excellence (NICE) Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 932
2023     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 931